Over the weekend officials in the Democratic Republic of the Congo (DRC) confirmed 11,000 doses of Johnson & Johnson’s Ebola vaccine (known as the J&J vaccine) had arrived in country, a development that’s been in the works for months as that country battles the second-largest Ebola outbreak in history.

The 11,000 doses are part of 50,000 to be used in a clinical trial evaluating the efficacy of the vaccine in an outbreak setting. The Ad26.ZEBOV, MVA-BN-Filo vaccine will be given to adults and children over the age of 1 in two doses, spaced 2 months apart. The vaccine was developed by Janssen and Bavarian Nordics in 2014 to target the Ebola Zaire strain.

Vaccine use outside of outbreak areas

(CC BY 2.0), flickr, Aalok Kanani

Read more at CIDRAP…